Researchers identify a novel player in acute myeloid leukemia

RNF5 is required for AML growth. The protein could be inhibited or used as a biomarker to improve patient outcomes.

Sanford Burnham Prebys drug enters Phase 1 study for the treatment of tobacco use disorder

A drug discovered in the lab of Nicholas Cosford, Ph.D., professor and deputy director of the NCI-designated Cancer Center at Sanford Burnham Prebys, has entered a Phase 1 clinical study.

Advocates for our Cancer Center ensure patient perspective is understood in the lab

Spotlight: Helen Eckmann and Ruth Claire Black share a common history with breast cancer and a drive to serve their community.